MedTrace Logo

Study on the Use of Artificial Intelligence (Fujifilm) for Polyp Detection in Colonoscopy

NCT04894708 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1572

Last updated 2023-06-28

No results posted yet for this study

Summary

Colonoscopy is currently the best method of detection of intestinal tumors and polyps, particularly because polyps can also be biopsied and removed. There is a clear correlation between the adenoma detection rate and prevented carcinomas, so adenoma detection rate is the main parameter for the outcome quality of diagnostic colonoscopy. The efficiency of preventive colonoscopy needs optimisation by increase in adenoma detection rate, as it is known from many studies that approximately 15-30% of all adenomas can be overlooked. This mainly applies to smaller and flat adenomas. However, since even smaller polyps may be relevant for colorectal cancer development, the aim of colonoscopy should be to preferably be able to recognize all polyps and other changes.The latest and by far the most interesting development in this field is the use of artificial intelligence systems. They consist of a switched-on software with a small computer connected to the endoscope processor; the patient's introduced endoscope is completely unchanged.

The present study therefore compares the adenoma detection rate (ADR) of the latest generation of devices with high-resolution imaging from Fujifilm with and without the connection of artificial intelligence.

Conditions

  • Screening Colonoscopy
  • Colonoscopic Control After Polypectomy
  • Suspected Colon Polyps

Interventions

PROCEDURE

colonoscopy

addition of polyp detection algorithm by Fujifilm

Sponsors & Collaborators

  • FUJIFILM Deutschland, Branch office of FUJIFILM Europe GmbH

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Thomas Rösch, Prof. dr. · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2024-05-31
Completion
2024-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04894708 on ClinicalTrials.gov